NCT06475495View on ClinicalTrials.gov

Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

13

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions

Rheumatoid Arthritis

Interventions

DRUG

KYV101

an autologous fully-human anti-CD19 CAR T-cell immunotherapy

DRUG

Rituximab (active comparator)

anti CD20 monoclonal antibody

Sponsors

Collaborators (1)

Kyverna Therapeutics

All Listed Sponsors

collaborator

Kyverna Therapeutics

INDUSTRY

lead

Charite University, Berlin, Germany

OTHER

NCT06475495 - Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter